VEGFA and age-related macular degeneration: Another study comparing mortality over time in patients treated with bevacizumab for AMD compared to patients for whom there was no record of a prescription for an anti‐VEGF agent found increased mortality within 3 months after a cerebrovascular event (OR = 6.92, 95%, CI 1.88–25.43, p < 0.01), within 6 months (OR = 2.00, 95%, CI 0.96–4.16, p = 0.064) while the risk was insignificant within 12 months (OR = 1.30, 95%, CI 0.75–2.26, p = 0.348) (Hanhart et al., 2018).